Caplin Point Lab
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Caplin Point Laboratories is positioned for steady growth, bolstered by management's focus on expanding its core Emerging Markets business and the promising trajectory of its US operations, particularly Caplin Steriles. Recent earnings calls highlight a disciplined execution strategy, with a significant capital expenditure plan aimed at enhancing capacity and product offerings. The anticipated commissioning of new facilities and a robust pipeline of product filings in the US and Mexico are expected to drive revenue growth and maintain stable margins. Vista's financial outlook reflects this optimism, projecting consistent revenue growth and stable profit margins, supported by a conservatively financed balance sheet. However, the company faces challenges from competitive pressures and the need for successful execution of its growth strategies. The macro environment remains favorable, with a stable inflation outlook and strong manufacturing activity in India, which supports the overall growth narrative for the Pharma APIs and CRAMS sector. Over the next 12-24 months, key opportunities include market expansion in Latin America and the US, while watchpoints include regulatory risks and the management of elevated receivables
Why We Like This Stock
- Management's focus on expanding into new markets, particularly in Latin America and the US, is expected to enhance revenue streams
- A significant capital expenditure plan aimed at capacity augmentation and product diversification supports long-term growth
- Stable profit margins and a conservatively financed balance sheet provide a solid foundation for sustainable expansion
Things To Watch Out For
- Competitive pressures in the Pharma APIs and CRAMS sector may impact market share and pricing power
- Execution risks associated with ambitious growth strategies and new facility commissioning could affect timelines
- Elevated receivables pose a temporary risk to cash flow, necessitating careful management
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 1,694 | 1,937 | 2,187 | 2,337 | 2,593 |
| Profit Before Tax (Cr.) | 563 | 677 | 803 | 858 | 951 |
| PBT Margin | 33.2% | 35.0% | 3671.7% | 36.7% | 36.7% |
| Net Profit (Cr.) | 462 | 551 | 657 | 702 | 769 |
| Earnings Per Share | 60.2 | 71.9 | 85.4 | 91.2 | 101.2 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag formulations, inhalers, and sprays and IV infusion. It also provides dry and syrups, lyophilized vials, prefilled syringes, emulsion injection, sachets, liquid injectables, topicals, pre-filled syringes, and pre-mix bags. Caplin Point Laboratories Limited was incorporated in 1990 and is headquartered in Chennai, India.